Cargando…

Humoral and T-cell response to SARS-CoV-2 mRNA BNT162b2 vaccination in a cohort of kidney transplant recipients and their cohabitant living kidney donor partners

Detalles Bibliográficos
Autores principales:	La Milia, Vincenzo, Tonolo, Silvia, Luzzaro, Francesco, Bonato, Claudio, Casartelli, Donatella, Limardo, Monica, Longhi, Selena, Ravasi, Chiara, Viganò, Sara, Cavalli, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967661/ https://www.ncbi.nlm.nih.gov/pubmed/35371437 http://dx.doi.org/10.1093/ckj/sfac010

Ejemplares similares

Sustained humoral response 6 months after the anti-SARS-CoV-2 mRNA-BNT162b2 vaccine in haemodialysis patients: should booster vaccine doses be given to all patients at the same time?
por: La Milia, Vincenzo, et al.
Publicado: (2022)

COVID-19 Outbreak in a Large Hemodialysis Center in Lombardy, Italy
por: La Milia, Vincenzo, et al.
Publicado: (2020)

Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases
por: Leung, Daniel, et al.
Publicado: (2023)

Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients
por: De Cagna, Maria Rosaria, et al.
Publicado: (2023)

Factors associated with humoral response after BNT162b2 mRNA COVID-19 vaccination in kidney transplant patients
por: Ducloux, Didier, et al.
Publicado: (2021)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
por: Miyazaki, Ryoichi, et al.
Publicado: (2023)

A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response
por: Masset, Christophe, et al.
Publicado: (2021)

Low rates of humoral response to BNT162b2 SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases treated with rituximab
por: Demoulin, Nathalie, et al.
Publicado: (2021)

Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2021)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Aspects of Humoral Immunity after Vaccination with Bnt162b2: A Small Study
por: GIUBELAN, LUCIAN-ION, et al.
Publicado: (2022)

BNT162b2 vaccine effectiveness in chronic kidney disease patients—an observational study
por: Bielopolski, Dana, et al.
Publicado: (2022)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2022)

Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis
por: Dekervel, Marine, et al.
Publicado: (2021)

Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients
por: Agur, Timna, et al.
Publicado: (2022)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: No cause for alarm
por: Mossad, Sherif Beniameen
Publicado: (2021)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer
por: Di Noia, V., et al.
Publicado: (2022)

Serum C reactive protein predicts humoral response after BNT162b2 booster administration
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
por: Costard-Jäckle, Angelika, et al.
Publicado: (2022)

Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2
por: Rammauro, Florencia, et al.
Publicado: (2022)

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
por: Dalla Gasperina, Daniela, et al.
Publicado: (2023)

Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, following Vaccination with BNT162b2
por: Fylaktou, Asimina, et al.
Publicado: (2023)

Response to tozinameran (BNT162b2) booster in twice-vaccinated kidney transplant and maintenance dialysis patients
por: Ben-Dov, Iddo Z., et al.
Publicado: (2022)

Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children
por: Gulmez, Ruveyda, et al.
Publicado: (2022)

Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
por: Lukaszuk, Krzysztof, et al.
Publicado: (2021)

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2
por: Dann, Eldad J, et al.
Publicado: (2021)

Humoral Response of Patients With Autoimmune Rheumatic Disease to BNT162b2 Vaccine: A Retrospective Comparative Study
por: Alsaed, Omar, et al.
Publicado: (2022)

Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populations
por: Campagna, Roberta, et al.
Publicado: (2022)

Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
por: Mavrovouniotis, Ilias, et al.
Publicado: (2023)

The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
por: Cohen, Idan, et al.
Publicado: (2023)

Humoral and Cellular Response and Associated Variables Nine Months following BNT162b2 Vaccination in Healthcare Workers
por: Syrimi, Natalia, et al.
Publicado: (2023)

Six-Month Follow-Up after Vaccination with BNT162b2: SARS-CoV-2 Antigen-Specific Cellular and Humoral Immune Responses in Hemodialysis Patients and Kidney Transplant Recipients
por: Boedecker-Lips, Simone Cosima, et al.
Publicado: (2022)

Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients
por: Cassaniti, Irene, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ojgpf6focs43sot553ppsjpacl